Extensive stage small cell lung cancer-Reference-Cited by-同舟云学术

Extensive stage small cell lung cancer

Published:2001-01 Issue:1 Volume:2 Page:71-76
ISSN:1527-2729
Container-title:Current Treatment Options in Oncology
language:en
Short-container-title:Curr. Treat. Options in Oncol.

Author:

Niell Harvey B.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11864-001-0018-4.pdf

Reference51 articles.

1. Greenlee RT, Murray T, Bolden S, Wing PA: Cancer statistics, 2000. CA Cancer J Clin 1999, 49:8–31.

2. Zelen M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973, 4:31–40.

3. Abrams J, Doyle LA, Aisner J: Staging, prognostic features and special considerations in small cell lung cancer. Semin Oncol 1988, 15:261–277.

4. Aisner J, Alberts P, Bitran J, et al.: Role of chemotherapy is SCLC: a consensus report of the International association for the study of lung cancer workshop. Cancer Treat Rep 1983, 67:37–43.

5. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 1992, 327:1434–1437.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study;Investigational New Drugs;2017-03-15

2. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin;Lung Cancer;2012-12

3. Thorax;Leibel and Phillips Textbook of Radiation Oncology;2010

4. Nicotine Enhances the Antiapoptotic Function of Mcl-1 through Phosphorylation;Molecular Cancer Research;2009-11-10

5. Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Patients With Extensive Small-Cell Lung Cancer With Eastern Cooperative Oncology Group Performance Status of 2, or Age ≥ 70 Years;Journal of Clinical Oncology;2004-05-15